AGP Executive Report
Last update: 4 hours agoCancer Advances: FDA expanded talazoparib plus enzalutamide for HRR-mutated hormone-sensitive prostate cancer, while sacituzumab tirumotecan cut the risk of death by 32% in advanced endometrial cancer. The FDA also granted breakthrough status to enzomenib for a high-risk leukemia subtype. Drug Industry: South Korea’s bio-health exports rose 19.4% to a record $24.8 billion in the first nine months, powered by pharmaceuticals and biologics. Health IT: A new federal rule removes or revises health IT certification requirements, including narrowing rules for clinical decision-support tools, while retaining privacy and security criteria. Patient Safety: Low health literacy can make prescriptions and care instructions harder to follow, with consequences for health and healthcare costs.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[AI Twins Are Growing in the Pharma Industry]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/29777665-952346659-ff28f96f0dc11c791522c9438052c09f2a43af55-1280x720-200x113.jpeg)
![<![CDATA[Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC ]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/25797941-917671805-6f252d9f233ef843f6e3645d13882059fa2b2b03-5000x3750-100x75.jpeg)
